Medicare Coverage Advisors Will Consider Evidence For PAD Interventions
This article was originally published in The Gray Sheet
The Medicare Evidence Development and Coverage Advisory Committee is set to meet this summer to weigh evidence for lower-extremity peripheral artery disease interventions.
You may also be interested in...
Medtronic gained FDA approval for its drug-coated balloon for the peripheral artery, as expected, and it is now gunning to take share from first-to-market C.R. Bard with the help of impressive clinical data and a formidable Covidien peripheral vascular device sales force.
The market for peripheral vascular interventions and diagnostics is poised for significant growth in the years ahead, driven by an aging population and the growing incidence of peripheral vascular disease, along with new technological developments such as drug-eluting balloons, which are inching closer to regulatory approval in the US.
An expert panel foresees increased adoption of digital tools in the OR, not just robotics. These tools help surgeons make more informed decisions and improve outcomes, but barriers remain.